Japan's NMN and NAD+ Supplement Regulations in 2026: What Overseas Buyers Need to Know

Jun 9, 2026

Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before starting or adjusting any supplement regimen.

The interest in Japan’s longevity supplement market among overseas buyers tends to cluster around a practical question: is what you’re buying in a Japanese-branded product actually legal to import, and what kind of health claim, if any, does the regulatory system in Japan warrant? That question has become more specific in the NAD+ precursor category since the US FDA’s 2022 statement on NMN’s dietary supplement status, and it has become part of how buyers evaluate whether a domestic Japanese purchase or an import through Amazon or iHerb is the more defensible option.

This article covers the current regulatory landscape for the longevity supplement compounds most discussed by overseas health audiences: NMN and NR as NAD+ precursors compared across Japan, the US, and the EU, and the food-versus-supplement boundary questions currently applying to ashitaba chalcone and resveratrol. Japan’s Consumer Affairs Agency functional food notification pipeline provides the structural backdrop — how Japan’s system handles longevity-relevant compounds relative to how FDA and EFSA handle the same ingredients.

NMN’s position in Japan’s regulatory framework

In Japan, NMN is sold as a general health food supplement (健康食品) rather than under a pharmaceutical classification or a functional food claim. Japanese regulatory law distinguishes between pharmaceuticals (医薬品, regulated by MHLW under the Pharmaceutical and Medical Device Act), functional food claims under the FOSHU and FFC notification systems (regulated by the Consumer Affairs Agency), and general foods that make no specific health claims. NMN currently sits in the third category.

What that means practically: NMN products sold in Japan are not prohibited, but they are not permitted to carry the kind of approved claim language that an FFC-notified product can use. A product label cannot state that NMN supports a specific physiological outcome in the way that a lactobacillus-based FFC product can state it supports intestinal regulation — because NMN has not, as of mid-2026, accumulated FFC notification approvals for specific claims. The compound is present in Japan’s supplement market in substantial volume, but the Consumer Affairs Agency’s publicly searchable 届出DB has not reflected broad NMN-specific claim notifications of the kind that have come through for EPA/DHA, certain lactobacillus strains, or lutein.

Japanese pharmaceutical-scale NMN producers — Mitsubishi NMN and Shinkoso are the most prominent — operate under the 一般食品 framework and position products on production quality and bioavailability data rather than on approved claim language. That distinction between production pedigree and regulatory claim status matters when evaluating marketing. A product made by a Japanese pharmaceutical manufacturer is not a pharmaceutical product in the regulatory sense.

The practical upshot for overseas buyers: NMN from Japan is legally importable as a food supplement in most markets. What it is not is a product whose health claim language has been formally reviewed and approved by a Japanese government body. The human trial record — including work by Yoshino et al. (2021), Igarashi et al. (2022), and Liao et al. (2023) — has been conducted at institutional research level, not as part of a claim notification dossier submitted to the Consumer Affairs Agency. MHLW has not published specific NMN guidance documents that would alter the compound’s general food classification as of the most recent available records.

Japanese NMN supplements on Amazon covers the range of products available internationally, including formulations from Japanese producers. For the clinical trial evidence — what those RCTs actually tested and what outcomes they measured — Japanese NMN Research: What the RCTs Actually Show covers that separately.

NMN vs NR: the regulatory gap across three jurisdictions

The legal divergence between NMN and its close NAD+-precursor relative, nicotinamide riboside (NR), is the most practically significant regulatory fact in this space for US-based buyers.

In the United States, NR received New Dietary Ingredient (NDI) acknowledgment from the FDA through ChromaDex, giving it the clearer of the two legal footings as a dietary supplement under DSHEA. NMN’s situation diverges: in November 2022, the FDA concluded that NMN could not be lawfully marketed as a dietary supplement because it had been the subject of an Investigational New Drug (IND) application — a pathway that, under FDA’s interpretation, removes an ingredient from the dietary supplement definition. The FDA statement created regulatory ambiguity but did not trigger enforcement action. NMN products have continued to sell in the US market, and several stakeholders have challenged the FDA’s interpretation through formal comment processes. As of mid-2026, the regulatory question remains unsettled.

In the European Union, both NMN and NR are subject to the EU Novel Food Regulation (Regulation EU 2015/2283), which requires pre-market authorization for any food or food ingredient that was not consumed to a significant degree in the EU before May 15, 1997. Neither compound has received Novel Food authorization from EFSA as of the most recent available information, meaning their sale as supplements in EU member states is in a legally contested position — notwithstanding availability through online channels. EFSA’s assessment process requires evidence of safety at the proposed intake levels and a determination of consumption history. The outcome of pending applications will determine whether either compound can be marketed with claim language in EU-governed markets.

In Japan, the relevant framework differs from both. Neither compound requires pharmaceutical-equivalent pre-market approval to be sold as a general health food, and neither has achieved FFC notification status for specific health claims. The result is a Japanese market that is legally functional for both NMN and NR but claim-language-constrained — a different kind of ambiguity than the US or EU situations, but ambiguity nonetheless.

NMN vs NR: What Human Trials Actually Compare covers the clinical evidence comparison in detail — dose ranges, bioavailability data, and what the trial record showed across the two precursors.

Tru Niagen NR supplements on Amazon covers the main NR formulations available with NDI-acknowledged status.

Ashitaba chalcone and resveratrol: the food-versus-supplement boundary

Two other longevity-relevant compounds raise a related but distinct regulatory question: when does a Japanese plant food’s active compound cross into supplement territory, and what does that mean for the claim language it can carry?

Ashitaba (Angelica keiskei) is a traditional food plant native to the Izu Islands and coastal regions of Japan. Consumed as a vegetable — in salads, tempura, and green tonics — it sits unambiguously in the food category. Its chalcone compounds, particularly 4-hydroxyderricin and xanthoangelol, are present in the plant at food-grade concentrations and have been studied in research examining their association with autophagy-related pathways in model organisms including C. elegans and Drosophila. When ashitaba is extracted and concentrated into capsule or tablet form at doses that exceed typical dietary intake, the regulatory classification shifts: in Japan, the concentrated extract moves into the supplement category. FFC notifications for ashitaba-based extracts are a minority of the overall notification database, and human clinical evidence for claim-level outcomes remains preliminary — consistent with a research-to-notification gap for newer botanical ingredients. The food form and the supplement form are distinct regulatory objects.

Resveratrol, most commercially sourced from Japanese knotweed (Reynoutria japonica, also Fallopia japonica), follows a parallel pattern. The plant itself has traditional use in Japan and China; in Japan it is known as 虎杖 (itadori) and is consumed as a spring vegetable in some regions. The trans-resveratrol compound extracted from it and sold in supplement form is a different regulatory object from the plant food. In the United States, trans-resveratrol is sold as a dietary supplement under DSHEA without novel-food pre-market requirements. In the EU, resveratrol supplements are subject to Novel Food authorization procedures; EFSA’s previous assessment of resveratrol-containing products did not result in an authorized health claim, and products using resveratrol from Japanese knotweed as a supplement require authorization that has remained pending across multiple applications. In Japan, resveratrol supplements sold without FFC notifications sit in the general food category — permissible but claim-language-constrained.

The pattern across ashitaba chalcone and resveratrol is consistent: Japanese origin provides research history and production infrastructure, but neither compound currently has a regulatory pathway to specific health claims within Japan’s formal FFC or FOSHU framework. The distinction between the food context in which these compounds were traditionally consumed and the concentrated supplement form in which they are currently sold is not merely semantic — it affects what evidence is considered adequate for claim support and what a label may legally say.

Ashitaba and Autophagy: What the Japanese Chalcone Research Shows covers the research side in depth. Resveratrol from Japanese Knotweed: What the SIRT1 Research Shows covers the resveratrol evidence trail, including where human trial data runs thin.

Ashitaba Angelica keiskei supplements on Amazon covers current internationally available formulations for buyers considering this category.

The Consumer Affairs Agency’s FFC pipeline and longevity compounds

Japan’s 機能性表示食品 (FFC) system has grown from approximately 210 notifications at its April 2015 launch to over 6,000 active notifications, and the composition of that database reflects which ingredient-claim combinations have assembled sufficient evidence for notification. The longevity-adjacent compound categories that have moved through the FFC pipeline most successfully share a structural feature: they have accumulated specific, claim-relevant human trial data with measurable endpoints — lactobacillus strains for intestinal flora markers, EPA/DHA for blood triglyceride response, lutein for visual function indicators, and plasmalogen for cognitive function markers in earlier-stage submissions.

NMN and the compounds discussed above are not well-represented in the FFC notification database in the same form. The reason is evidence-structural rather than regulatory hostility: FFC notification requires a systematic review of published trials showing that the specific ingredient at the specific dose is associated with the specific claimed outcome. The human trial record for NMN, ashitaba chalcone, and resveratrol in humans is less mature than the record for the FFC’s established claim categories — a gap that accurately describes their current status, not a policy judgment about the compounds’ research directions.

The Q1 and Q2 2026 trajectory of new FFC notifications has continued consistent with prior years: the Consumer Affairs Agency continues processing notifications across established and emerging ingredient categories, with the database growing through the agency’s standard 60-business-day review window. The 届出DB remains the authoritative public record — searchable by ingredient, claim category, and submission date, and accessible with translation tools for non-Japanese readers.

Japan’s Functional Food Regulations: FOSHU, FFC, and Why Label Language Matters covers the full mechanics of both regulatory tiers, including the evidentiary standards the notification system requires. Japan Longevity Research Q3 2026: Four Developments in the Research Calendar covers the broader research and regulatory pipeline context for mid-2026.

What overseas buyers can act on

The regulatory picture here does not resolve into a single purchase recommendation — which is consistent with the factual state of affairs.

NMN from Japanese manufacturers like Mitsubishi NMN and Shinkoso carries production quality credentials that most US-brand NMN lacks, regardless of the US FDA’s regulatory ambiguity around the compound’s dietary supplement classification. NR through ChromaDex’s Tru Niagen has the clearer US regulatory pathway. The clinical evidence for what each actually does in healthy adults remains preliminary; neither compound is in a position where regulatory claim language and the evidentiary record overlap cleanly. Sirtuins, NAD+, and Caloric Restriction: What the Molecular Pathway Research Shows provides the mechanistic context for why the NAD+ precursor category attracts ongoing research interest.

For buyers in the EU, both NMN and NR sit in uncertain Novel Food territory. A healthcare professional familiar with the regulatory and safety picture for your jurisdiction is the appropriate consultation point before purchasing either compound, particularly at the higher end of the dose ranges appearing in trial protocols.

The Consumer Affairs Agency’s 届出DB functions as a useful cross-reference for the Japan-sourced supplement market: when a compound category achieves FFC notification status, it means a manufacturer has submitted a systematic evidence review that the agency reviewed and did not object to. Checking whether a product category has FFC notifications on record is a concrete due-diligence step that costs nothing. The fact that NMN and most longevity-associated compounds are not yet represented there is itself informative about where the evidence currently stands relative to the evidentiary bar the notification system sets.

Health Japan 21’s Third Phase: What Japan’s 2024–2032 National Health Targets Say provides the MHLW policy context behind Japan’s approach to supplement regulation as part of a broader national healthy-aging framework.